10,958 Shares in Illumina, Inc. (NASDAQ:ILMN) Bought by Strategic Financial Concepts LLC

Strategic Financial Concepts LLC bought a new position in Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 10,958 shares of the life sciences company’s stock, valued at approximately $1,464,000.

Several other large investors have also made changes to their positions in the company. Cetera Investment Advisers increased its holdings in Illumina by 25.8% in the 2nd quarter. Cetera Investment Advisers now owns 18,384 shares of the life sciences company’s stock valued at $1,919,000 after purchasing an additional 3,767 shares in the last quarter. CWM LLC increased its holdings in Illumina by 179.8% in the 3rd quarter. CWM LLC now owns 16,207 shares of the life sciences company’s stock valued at $2,114,000 after purchasing an additional 10,414 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt increased its holdings in Illumina by 323.9% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,047 shares of the life sciences company’s stock valued at $136,000 after purchasing an additional 800 shares in the last quarter. Valeo Financial Advisors LLC acquired a new stake in shares of Illumina during the third quarter valued at about $276,000. Finally, Compagnie Lombard Odier SCmA grew its stake in shares of Illumina by 2,013.3% during the third quarter. Compagnie Lombard Odier SCmA now owns 1,585 shares of the life sciences company’s stock valued at $207,000 after acquiring an additional 1,510 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on ILMN. Morgan Stanley lowered their target price on Illumina from $156.00 to $150.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Citigroup cut shares of Illumina from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $190.00 to $165.00 in a research report on Wednesday, December 11th. Royal Bank of Canada reduced their price target on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research report on Friday. Guggenheim reduced their price target on shares of Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Robert W. Baird increased their price target on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $160.15.

Illumina Trading Down 5.5 %

NASDAQ ILMN opened at $104.99 on Tuesday. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a twelve month low of $100.08 and a twelve month high of $156.66. The company has a market cap of $16.65 billion, a price-to-earnings ratio of -13.67 and a beta of 1.10. The business’s fifty day moving average is $136.70 and its 200 day moving average is $135.56.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 12.59% and a negative net margin of 27.95%. As a group, sell-side analysts expect that Illumina, Inc. will post 4.42 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.